About

Dr. Véronique Lecault is a co-founder of AbCellera and has served in various positions since November 2012, as a member of the Board of Directors since August 2018, as Chief Operating Officer from January 2019 to February 2025, and as Chief Technology Officer since February 2025. She co-invented the high-throughput microfluidic platform that is now a core part of AbCellera's antibody-discovery technology and oversees the company's process development, clinical manufacturing, quality, engineering, data science and infrastructure functions. She holds a B.A.Sc. in Chemical Engineering / Honours B.Sc. in Biochemistry (Biotechnology) from the University of Ottawa and a Ph.D. in Chemical and Biological Engineering from the University of British Columbia.

Roles

AbCellera Biologics Inc.
Chief Technology Officer and Director · Current role
November 2012–present
AbCellera Biologics Inc.
Chief Operating Officer · Transitioned to Chief Technology Officer effective February 18, 2025
January 2019 - February 2025
University of British Columbia
Ph.D. researcher · Co-invented the high-throughput microfluidic platform underlying AbCellera's core technology

Fixed Compensation

FY 2025
Salary
$454,000
ComponentAnnual base salary earned in FY2025 (USD)
All other compensation
$23,244
ComponentRRSP employer contributions
Total compensation
$2,315,758

Performance Compensation

Data from FY 2025

Cash incentive

Bonus
$204,402
Target Opportunity
PlanDiscretionary annual cash incentive bonus for 2025 (45% of base-salary target)

Stock awards

Stock options
$1,634,113
FormStock options, ASC 718 grant-date fair value (NEO long-term incentives are 100% options)

Also at AbCellera Biologics Inc.

Related

See how VectorShift works for your firm

Request Demo